ArticleEndocrinology2025
Blood-Brain Barrier Integrity and Transport of Major Hormones are Unchanged in Mice With Euglycemic Hyperinsulinemia.
Article in Endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
High-fat diet (HFD) consumption increases the risk of metabolic syndrome as manifested by insulin resistance, fatty liver, hypertriglyceridemia, and diabetes mellitus type 2. Blood-brain barrier (BBB) disruptions and impaired BBB transport of metabolic hormones, including leptin, insulin, and ghrelin, occur in diabetes mellitus type 2 and contribute to metabolic dysregulation and cognitive impairment. However, it is unclear whether the BBB changes are caused by the HFD, obesity, insulin resistance, elevated glucose or triglyceride levels, or other aspects of the metabolic syndrome. This study examined the effects of chronic HFD and an early stage of metabolic syndrome on BBB disruption and transport of insulin, leptin, and ghrelin. Mice on the HFD demonstrated obesity, increases in insulin, leptin, plasminogen activator inhibitor-1, and resistin, fatty liver and hyperglycerolemia, without elevations in glucose, triglycerides, ghrelin, glucagon, gastric inhibitory polypeptide, or glucagon-like peptide. The vascular markers of sucrose and albumin did not show BBB disruption. HFD did not alter the rate of insulin, leptin, or ghrelin transport across the BBB. However, leptin binding to the luminal surface of the BBB was greater in the hypothalamus and reduced for the rest of the brain with HFD treatment. The liver uptake of insulin, leptin, and ghrelin was reduced in the HFD group. Overall, our findings indicate that chronic HFD consumption with concomitant obesity and insulin resistance in the absence of hyperglycemia does not result in BBB disruption or altered BBB permeability to key metabolic hormones but may selectively affect vascular binding of important metabolic hormones in the brain and liver.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.